|
Protocol ID |
Official Title |
Principal Investigator |
Lead CRC |
Disease Site |
Phase |
|
STRO-002-GM1 ClinicalTrials.gov # |
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRa) Antibody Drug Conjugate (ADC) in Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancer |
Dr. Sharad Ghamande |
Ovarian and Endometrial Cancers |
I |
|
|
TESARO 4010-01-001 ClinicalTrials.gov # |
Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors |
Dr. Sharad Ghamande |
Advanced solid tumors |
I |
|
|
MORAb-202-G000-201 ClinicalTrials.gov # |
A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRa)-Targeting Antibody-Drug Conjugate (ADC) in Subjects with Selected Tumor Types |
Dr. Sharad Ghamande |
Endometrial, Ovarian, or Peritoneal Cancer |
I/II |
|
|
EP0057-201 ClinicalTrials.gov # |
A Phase 2 Study to Evaluate the Safety and Efficacy of EP0057 in Combination With Olaparib in Advanced Ovarian Cancer Patients Who Have: Cohort 1 Platinum Resistant Disease and are PARP Inhibitor Naïve; Cohort 2 Had at Least 2 Prior Lines of Therapy Which Must Include at Least 1 Line of Platinum-Based Chemotherapy Followed by PARP Inhibitor Maintenance |
Dr. Sharad Ghamande |
Ovarian Cancer |
II |
|
|
LION C-145-04 ClinicalTrials.gov # |
A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma |
Dr. Sharad Ghamande |
Cervical Cancer |
II |
|
|
NRG-GY006 ClinicalTrials.gov # |
A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer |
Dr. Sharad Ghamande |
Sara Mobley |
Uterine Cervical or Vaginal Cancer |
II |
|
NRG-GY009 ClinicalTrials.gov # |
A Randomized, Phase II/III Study of Pegylated Lipsomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer |
Dr. Sharad Ghamande |
Ovarian Cancer |
II/III |
|
|
GOG-3031/4010-03-001 ClinicalTrials.gov # |
A Phase 3, Randomized, Double-blind, Multicenter Study of TSR-042 plus Carboplatin-Paclitaxel versus Placebo plus Carboplatin-Paclitaxel in Patients with Recurrent or Primary Advanced Endometrial Cancer |
Dr. Sharad Ghamande |
Endometrial |
III |
|
|
GOG-3057/SGNTV-003 ClinicalTrials.gov # |
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer |
Dr. Sharad Ghamande |
Cervical |
III |
|
|
GOG-3059/AVB500-OC-004 ClinicalTrials.gov # |
A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer |
Dr. Sharad Ghamande |
Ovarian |
III |
